Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VS 7375

Next Previous
Drug Profile

VS 7375

Alternative Names: GFH-375; GFH375/VS-7375; VS-7375

Latest Information Update: 09 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GenFleet Therapeutics
  • Developer GenFleet Therapeutics; Verastem Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 03 Dec 2025 GenFleet Therapeutics plans a phase-III trial for Pancreatic cancer(Metastatic disease, Second-line therapy or greater) in December 2025 (PO), (NCT07262567)
  • 14 Nov 2025 Genfleet Therapeutics withdraws a phase II trial prior to enrollment for Pancreatic cancer (Monotherapy, Second-line therapy or greater, Metastatic disease) (PO) due to adjustment of product development strategy (NCT07026916)
  • 22 Oct 2025 Pharmacodynamics data from preclinical trials in Solid tumours presented at the International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top